New Biological Treatment for Diabetes Shows Promise

❗️The cell therapy trial has shown promising results in improving insulin sensitivity and reducing the reliance on insulin injections in patients with type 2 diabetes.

✨The therapy focuses on reviving damaged beta cells in the pancreas instead of replacing them with new healthy cells.

🌍The potential impact of this treatment could benefit millions of individuals living with diabetes worldwide.

🔬The treatment utilizes perinatal tissue-derived cells, which originate from either the placenta or the umbilical cord.

💊Patients undergoing the treatment do not need to take immunosuppressant medications, reducing the risk of adverse side effects.

What is the purpose of the cell therapy trial?

—The purpose of the cell therapy trial is to improve insulin sensitivity and reduce the reliance on insulin injections in patients with type 2 diabetes.

How does the therapy revive damaged beta cells?

—The therapy aims to revitalize the beta cells that are already present in the pancreas, rather than replacing them with new cells.

What are perinatal tissue-derived cells?

—Perinatal tissue-derived cells are cells that originate from either the placenta or the umbilical cord.

Do patients undergoing the treatment need to take immunosuppressant medications?

—No, patients undergoing the treatment do not need to take immunosuppressant medications, reducing the risk of adverse side effects.

How could this treatment benefit individuals with diabetes worldwide?

—The treatment has the potential to benefit millions of individuals worldwide by improving insulin sensitivity and reducing the reliance on insulin injections.

00:11A new cell therapy trial has shown positive results in lowering insulin levels in patients with type 2 diabetes.

00:23The therapy aims to revive damaged beta cells in the pancreas, potentially reducing the reliance on insulin injections.

01:07The therapy has shown promising results in improving insulin sensitivity and reducing the need for insulin.

02:32The treatment utilizes perinatal tissue-derived cells, which originate from either the placenta or the umbilical cord.

03:02Patients undergoing the treatment do not need to take immunosuppressant medications, reducing the risk of adverse side effects.

03:21The ongoing clinical trial for the cell treatment program has produced excellent findings within a year.

04:02The therapy aims to revitalize the beta cells that are already present in the pancreas, rather than replacing them with new cells.

05:53The potential impact of this therapy on diabetes treatment could affect millions of individuals around the world.